ArticleJACC. Case reports2025
Percutaneous Orthotopic Transcatheter Tricuspid Valve Replacement for Native Valve Destruction After Endocarditis.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTranscatheter tricuspid valve replacement (TTVR) is emerging as an option for treating severe tricuspid regurgitation (TR) in patients at high surgical risk. CASE SUMMARY: A 59-year-old man with torrential TR and right heart failure following Staphylococcus aureus tricuspid valve infective endocarditis and extensive leaflet destruction was successfully treated with orthotopic TTVR using the LuX-Valve Plus system (Jenscare), resulting in significant clinical improvement and favorable right ventricular remodeling. DISCUSSION: The LuX-Valve Plus, delivered via transjugular access, enables optimal coaxial alignment during deployment. Its unique features-leaflet graspers, a septal anchoring mechanism, and a flexible frame-provide stability and preserve right ventricular function, making it suitable for complex tricuspid anatomies. TAKE-HOME MESSAGES: Orthotopic TTVR with the LuX-Valve Plus offers a viable option for patients with severe TR and extensive leaflet destruction, previously considered ineligible for surgical or transcatheter repair. Multimodality imaging is essential for procedural planning and optimal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.